The Conversation (0)
Lobe Sciences (OTC Pink: GTSIF) today announced that Philip Young, CEO & Director will be attending the Q4 Virtual Investor Summit. Millions of people are experiencing the devastating, often long-term effects of mTBI (mild traumatic brain injury) and PTSD (post-traumatic stress disorder), with few, if any, effective treatments available. Our goal is to change that fact, and during this presentation, Philip Young, CEO & Director, will outline a path for the development of therapeutics for which Lobe Sciences intends to seek FDA approval in the United States, and similar approvals internationally.
| Â | Event: | Q4 Investor Summit |
| Â | Date: | November 16-17th, 2021 |
| Â | Presentation: | November 17th at 11:00 AM ET |
| Â | Location: | https://us06web.zoom.us/webinar/register/WN_ecoTV7Y1Rmmfr_5yjDFvXQ |
Â
- 1x1s will be available for qualified investors
- The conference is completely complimentary to qualified investors. Please register at Complimentary Investor Registration
About Lobe Sciences
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information:
Lobe Sciences
Philip Young
(949) 505-5623
info@lobesciences.com
About the Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising of institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: info@investorsummitgroup.com
